Shenzhen Kangtai Biological Products

Shenzhen Kangtai Biological Products
Company type	Public
Traded as	SZSE: 300601
ISIN	CNE100002Q33
Founded	September 8, 1992; 31 years ago
Founder	Du Weimin
Headquarters	6 Kefa Road, Science and Technology Park, Nanshan District, Shenzhen, Shenzhen, China
Number of employees	2043
Chinese name
Simplified Chinese	深圳康泰生物制品股份有限公司
Hanyu Pinyin
Transcriptions
Standard Mandarin
Hanyu Pinyin	Shēnzhèn Kāngtài Shēngwù Zhìpǐn Gǔfèn Yǒuxiàn Gōngsī
Website	en.biokangtai.com

22°32′48″N 113°56′37″E / 22.5467°N 113.9437°E / 22.5467; 113.9437

Shenzhen Kangtai Biological Products (Chinese: 深圳康泰生物制品股份有限公司, SZSE: 300601), also known as BioKangtai (Chinese: 康泰生物), is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.^[2]

Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China.^[3]^[4]^[1]

References

^ ^a ^b "Scandal Dogs AstraZeneca's Vaccine Partner in China". The New York Times. 7 January 2021. Retrieved 1 August 2021.
^ ^a ^b "Shenzhen Kangtai Biological Products Co Ltd". Bloomberg. Retrieved 1 August 2021.
^ "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. 14 May 2021. Retrieved 1 August 2021.
^ "AstraZeneca's China partner expects to be able to make 400 million COVID-19 vaccine doses a year". Reuters. 2 February 2021. Retrieved 1 August 2021.

This Chinese corporation or company article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Shenzhen_Kangtai_Biological_Products
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[nyt-history-controversies-1] "Scandal Dogs AstraZeneca's Vaccine Partner in China". The New York Times. 7 January 2021. Retrieved 1 August 2021.

[bloomberg-profile-2] "Shenzhen Kangtai Biological Products Co Ltd". Bloomberg. Retrieved 1 August 2021.

[3] "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. 14 May 2021. Retrieved 1 August 2021.

[4] "AstraZeneca's China partner expects to be able to make 400 million COVID-19 vaccine doses a year". Reuters. 2 February 2021. Retrieved 1 August 2021.

[1]

[2]

[3]

[4]